Home » Stocks » BioCardia

BioCardia, Inc. (BCDA)

Stock Price: $2.05 USD -0.08 (-3.76%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 25.47M
Revenue (ttm) 474,000
Net Income (ttm) -15.46M
Shares Out 12.43M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $2.05
Previous Close $2.13
Change ($) -0.08
Change (%) -3.76%
Day's Open 2.15
Day's Range 2.02 - 2.15
Day's Volume 55,162
52-Week Range 2.01 - 6.75

More Stats

Market Cap 25.47M
Enterprise Value 15.78M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.43M
Float 8.00M
EPS (basic) -2.24
EPS (diluted) -2.20
FCF / Share -1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 30,440
Short Ratio 0.35
Short % of Float 0.38%
Beta 2.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 53.74
PB Ratio 3.92
Revenue 474,000
Operating Income -14.95M
Net Income -15.46M
Free Cash Flow -10.10M
Net Cash 9.69M
Net Cash / Share 0.78
Gross Margin -1,735.73%
Operating Margin -3,152.95%
Profit Margin -3,261.60%
FCF Margin -2,129.75%
ROA -117.92%
ROE -611.71%
ROIC 1,336.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(686.34% upside)
Current: $2.05
Target: 16.12
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth13.6%30.48%-16.84%-36.28%111.71%59.33%332.26%416.67%--
Gross Profit0.350.11-0.21-0.17-0.160.430.270.060.01-
Operating Income-14.21-14.10-12.41-7.61-5.410.230.01-0.34-0.62-0.58
Net Income-14.71-13.99-12.31-10.31-6.700.230.020.319.66-11.51
Shares Outstanding5.644.264.240.930.
Earnings Per Share-2.61-3.28-2.90-11.07-38.61---4.32-5.40
Operating Cash Flow-9.45-11.07-8.67-5.52-
Capital Expenditures-0.15-0.07-0.14--0.13----0.14-1.07
Free Cash Flow-9.59-11.14-8.81-5.52-
Cash & Equivalents5.595.3612.6921.353.5613.5113.3013.2713.580.16
Total Debt1.14---6.72----0.50
Net Cash / Debt4.445.3612.6921.35-3.1613.5113.3013.2713.58-0.34
Book Value2.373.7911.1320.58-3.4413.5413.3113.2912.983.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioCardia, Inc.
Country United States
Employees 20
CEO Peter Alan Altman

Stock Information

Ticker Symbol BCDA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCDA


BioCardia, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.